MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on February 27, 2006; DOI: 10.1124/mol.105.019653


0026-895X/06/6906-2027-2036$20.00
Mol Pharmacol 69:2027-2036, 2006

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.105.019653v1
69/6/2027    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Letoha, T.
Right arrow Articles by Duda, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Letoha, T.
Right arrow Articles by Duda, E.

In Vitro and in Vivo Nuclear Factor-{kappa}B Inhibitory Effects of the Cell-Penetrating Penetratin Peptide

Tamás Letoha, Erzsébet Kusz, Gábor Pápai, Annamária Szabolcs, József Kaszaki, Ilona Varga, Tamás Takács, Botond Penke, and Erno Duda

Departments of Medical Chemistry (T.L., B.P.), Genetics and Molecular Biology (I.V.), and Medical Biology (E.D.), and First Department of Medicine (A.S., T.T.), University of Szeged, Szeged, Hungary; Biological Research Center of the Hungarian Academy of Sciences, Szeged, Hungary (E.K., G.P.); and Institute of Surgical Research, University of Szeged, Szeged, Hungary (J.K.)

Penetratin is a cationic cell-penetrating peptide that has been frequently used for the intracellular delivery of polar bioactive compounds. Recent studies have just revealed the major role of polyanionic membrane proteoglycans and cholesterol-enriched lipid rafts in the uptake of the peptide. Both proteoglycans and lipid-rafts influence inflammatory processes by binding a wide array of proinflammatory mediators; thus, we decided to analyze the effect of penetratin on in vitro and in vivo inflammatory responses. Our in vitro luciferase gene assays demonstrated that penetratin decreased transcriptional activity of nuclear factor-{kappa}B (NF-{kappa}B) in tumor necrosis factor (TNF)-stimulated L929 fibroblasts and lipopolysaccharide-activated RAW 264.7 macrophages. Penetratin also inhibited TNF-induced intercellular adhesion molecule-1 expression in human endothelial HMEC-1 cells. Exogenous heparan sulfate abolished the in vitro NF-{kappa}B inhibitory effects of the peptide. Uptake experiments showed that penetratin was internalized by all of the above-mentioned cell lines in vitro and rapidly entered the cells of the lung and pancreas in vivo. In an in vivo rat model of acute pancreatitis, a disease induced by elevated activities of stress-responsive transcription factors like NF-{kappa}B, pretreatment with only 2 mg/kg penetratin attenuated the severity of pancreatic inflammation by interfering with I{kappa}B degradation and subsequent nuclear import of NF-{kappa}B, inhibiting the expression of proinflammatory genes and improving the monitored laboratory and histological parameters of pancreatitis and associated oxidative stress.


Received for publication October 6, 2005.

Accepted for publication February 27, 2006.

Address correspondence to: Dr. Tamás Letoha, Department of Medical Chemistry, University of Szeged, Dóm tér 8, H-6720 Szeged, Hungary. E-mail: tletoha{at}yahoo.com




This article has been cited by other articles:


Home page
GutHome page
Z Rakonczay Jr, P Hegyi, T Takacs, J McCarroll, and A K Saluja
The role of NF-{kappa}B activation in the pathogenesis of acute pancreatitis
Gut, February 1, 2008; 57(2): 259 - 267.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics